Efficacy and safety of transepithelial collagen cross linking for progressive keratoconus

经上皮胶原交联治疗进行性圆锥角膜的疗效和安全性

阅读:1

Abstract

OBJECTIVE: To evaluate the efficacy and safety of transepithelial (TE) collagen cross-linking (CXL) in patients with progressive keratoconus (KC). METHODS: This Quasi Experimental Study was conducted at PNS Shifa Naval Hospital, Karachi from June 2015 to June 2016. Sixty eyes of 32 patients who underwent TE CXL for progressive KC from June 2015 to June 2016 were analysed to ascertain efficacy and safety of TE CXL procedure. Statistical analysis of the data was done using SPSS version 17.0. RESULTS: Twenty eight (87.5%) patients underwent TE CXL bilaterally, while 4 (12.5%) underwent unilateral CXL. Mean change in astigmatism, Maximum simulated Keratometry value (Kmax), Spherical equivalent (SE) and Central Corneal Thickness (CCT) were -0.67±0.35D, 1.28±0.64D, -0.58±0.17D and 0.40±7.58µm respectively, from baseline. Mean gain in lines on Snellen's visual acuity chart was 1.13±0.83 lines. Changes in astigmatism, Kmax and SE were statistically significant (p<0.001), while change in CCT was not statistically significant. The procedure had excellent safety profile, with no major complication till 6 months follow up period. CONCLUSION: TE CXL is a safe and effective procedure with statistically significant reduction in corneal astigmatism, Kmax and SE with reasonable gain in Snellen's visual acuity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。